| Names | |
|---|---|
| Preferred IUPAC name (5aR,11bS)-2-Propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]quinoline-9,10-diol | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C18H21NO2S | |
| Molar mass | 315.429 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist. [1] [2] It was developed as a possible treatment for Parkinson's disease, [3] as well as for other applications such as treatment of cocaine addiction, [4] [5] but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued. [6] [7] It has mainly been used as its diacetate ester prodrug adrogolide (ABT-431), which has better bioavailability. [8] [9]